A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
A phase 1/2 trial of Capecitabine, Atezolizumab, Ipatasertib, Bevacizumab, Carboplatin and Eribulin in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT03424005 by Hoffmann-La Roche, with 1132 participants planned, started 2018-03-30 and due to reach its primary completion in 2030-09-30. Interventions recorded: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab and Chemotherapy (Gemcitabine + Carboplatin or Eribulin).
Similar pages
not linked directly; found by shared links- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Eribulin, Gilead Sciences (incl. Kite), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Shares Ipatasertib, Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Eribulin, Capecitabine, Carboplatin and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.